HB 1090
In CommitteeHouse
Contraceptive coverage
Concerning contraceptive coverage.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill requires health insurance plans that cover contraceptives to allow patients to receive a full 12-month supply at one time, and to offer on-site dispensing when possible. It also clarifies what counts as a contraceptive drug and allows limited restrictions only in the final months of a plan year.
- Requires health plans that cover contraceptive drugs to allow enrollees to receive a 12-month supply of contraceptives in a single dispensing, unless the patient or provider requests less.
- Requires health plans to allow enrollees to receive contraceptive drugs on-site at the provider’s office, if available.
- Permits health plans to limit refills in the last quarter of the plan year *only* if a full 12-month supply has already been dispensed that year.
- Clarifies that "contraceptive drugs" includes all FDA-approved pregnancy-prevention drugs, regardless of route of administration (e.g., oral, patch, vaginal).
- Requires all dispensing practices to follow clinical guidelines to ensure patient safety while improving access.
Who is affected
- People seeking contraception — Employees and dependents covered by employer-sponsored or individual health plans that include contraceptive coverage; they gain easier access to longer-acting contraceptive methods by allowing a full year's supply to be dispensed at once.
- Health insurers and health plans — Health plans (including insurance companies and managed care organizations) must adjust their dispensing and refill policies to comply with the new requirement for 12-month supplies and on-site availability.
- Healthcare providers — Healthcare providers (e.g., doctors, clinics, pharmacies) must follow updated clinical guidelines and may need to adjust how they dispense or prescribe contraceptives, including offering on-site delivery where feasible.
- State regulatory agencies — State agencies responsible for regulating health insurance, such as the Office of the Insurance Commissioner, will need to monitor and enforce compliance with the new requirements.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (3)
Allowing a full 12-month supply at one time significantly reduces out-of-pocket costs (e.g., fewer copays, transportation, time off work) and improves adherence—especially for long-acting methods like IUDs or implants—directly benefiting low- and middle-income Washingtonians who otherwise face financial or logistical barriers to consistent contraception.
HealthcarePeopleRef: Sec. 1(1)Mandating on-site dispensing (where feasible) increases access for people in rural areas, those without nearby pharmacies, or those with mobility or transportation challenges—groups historically underserved in reproductive healthcare—while reducing delays in starting effective contraception.
HealthcarePeopleRef: Sec. 1(1)Explicitly including all FDA-approved contraceptive routes (oral, transdermal, intravaginal) ensures equitable access to diverse methods (e.g., patches, rings, gels), which is especially important for people with medical conditions that preclude certain formulations—supporting bodily autonomy and health equity.
HealthcarePeopleRef: Sec. 1(3)
Potential Concerns (3)
Mandating 12-month supply and on-site dispensing may increase administrative burden and operational complexity for small clinics and pharmacies with limited staffing or infrastructure, potentially delaying care or increasing costs for providers who lack on-site dispensing capability.
HealthcarePeopleRef: Sec. 1(1)Requiring on-site dispensing where “available” creates ambiguity and may disproportionately burden rural or under-resourced providers who lack space, staffing, or regulatory approval to dispense medications directly, potentially widening geographic access disparities.
HealthcareLean peopleRef: Sec. 1(1)The provision allowing plans to limit refills in the final quarter *only if* a 12-month supply was already dispensed may reduce flexibility for patients whose clinical needs change mid-year (e.g., due to side effects, weight changes, or new contraindications), potentially forcing them to switch methods or pay out-of-pocket for adjustments.
HealthcareRef: Sec. 1(2)
Who Is Most Affected
Low- and middle-income individuals—especially those on Medicaid, working without employer-sponsored insurance, or in rural communities—will benefit most: reduced out-of-pocket costs, fewer trips to clinics, and improved method continuity directly support reproductive autonomy and health outcomes.
Large health plans and pharmacy benefit managers may absorb costs more easily, but small clinics, independent pharmacies, and rural providers face higher relative compliance costs—especially for on-site dispensing infrastructure or staffing changes.
Providers in urban, well-resourced settings with dispensing infrastructure gain little extra burden but may see improved patient satisfaction; rural or underfunded clinics may face new operational or regulatory hurdles without additional state support.
The Office of the Insurance Commissioner gains enforcement responsibility but minimal new budget—no major fiscal strain, though monitoring compliance (especially on-site dispensing feasibility) may require modest staffing increases.